Research Training in Pulmonary Immunology and Allergy at MGH is a T32 renewal application that brings together research programs of the Massachusetts General Hospital (MGH) Division of Pulmonary and Critical Care Medicine (DPCCM), Allergy and Clinical Immunology Unit (ACIU), and Center for Immunology and Inflammatory Diseases (CIID). This Training Program was created principally to provide comprehensive training for physician-scientists in the DPCCM and ACIU fellowship programs interested in lung immunology and allergic inflammation. The Program is designed to prepare the next generations of physician-scientists and PhD-scientists to be leaders in lung immunology and allergy related research. In the first 3.5 years, this Program has been highly successful with no unfilled slots and 100% academic retention. In addition, all of the graduates of the Program have published at least one first-author publication and 73% have secured independent funding. In this renewal application we capitalize on this success and momentum and provide training in 10 scientific disciplines: (i) Adaptive Lung Immunity; (ii) Innate Lung Immunity; (iii) Allergic Sensitization, Tolerance & Immunodeficiency; (iv) Lung Injury, Repair & Regeneration; (v) Molecular Epidemiology & Genetics of Lung Disease and Allergy; (vi) Health Care Delivery Science in Pulmonary and Allergy; (vii) Translational & Precision Medicine; (viii) Systems Biology, Single Cell Genomics & Epigenetics; (ix) Microbiome; (x) Novel Imaging Modalities. The Program will have basic, translational, health outcomes and epidemiology components. Specifically we seek to provide: 1) opportunities for mentored research in disciplines that have the potential for high-impact discoveries; 2) outstanding research training through didactics, seminars, and comprehensive mentoring; and 3) an environment and infrastructure that fosters scholarly activity and career development into independent scientists. This application requests 10 training positions that will be allocated to trainees who are committed to 2 to 3 years of research training. Eight MD or MD/PhD candidates will be drawn from the highly competitive DPCCM and ACIU fellowship programs. Two PhD trainees will be chosen from postdoctoral fellows in the laboratories of our mentors who are performing at a high level and who have demonstrated a commitment to careers in pulmonary or allergy research. Two new slots for PhD trainees are being requested based on trainee and mentor feedback indicating that our Program would be strengthened, and the mission of the NIH better served, by having MDs and PhDs train side-by-side. The 28 mentors in this Program were carefully chosen based on their track record of publications, grants, mentoring, collaboration and interest in lung immunology and allergy. MGH provides an outstanding training environment with over 1400 investigators, numerous training grants, research centers, trainee support groups, and over $850 million in research grant awards. Furthermore, opportunities at Harvard Medical School, the Harvard School of Public Health, and the Broad Institute provide additional valuable resources for trainees.

Public Health Relevance

Research Training in Pulmonary Immunology and Allergy at MGH is designed to prepare the next generation of physician-scientists and PhD-scientists who, through mentored research and rigorous training in new technologies, will be well prepared to be leaders in pulmonary immunology and allergy related biomedical research. The overall goal of the program is to educate trainees so that they can contribute to our understanding of the basis of inflammatory lung disorders and allergic diseases, and translate these findings to better clinical care for patients with these important diseases.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Institutional National Research Service Award (T32)
Project #
5T32HL116275-08
Application #
9964875
Study Section
NHLBI Institutional Training Mechanism Review Committee (NITM)
Program Officer
Kalantari, Roya
Project Start
2013-07-01
Project End
2023-06-30
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
8
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02114
Keller, Sara C; Feldman, Leonard; Smith, Janessa et al. (2018) The Use of Clinical Decision Support in Reducing Diagnosis of and Treatment of Asymptomatic Bacteriuria. J Hosp Med 13:392-395
Mitton, Julian A; North, Crystal M; Muyanja, Daniel et al. (2018) Smoking cessation after engagement in HIV care in rural Uganda. AIDS Care 30:1622-1629
North, Crystal M; Allen, Joseph G; Okello, Samson et al. (2018) HIV Infection, Pulmonary Tuberculosis, and COPD in Rural Uganda: A Cross-Sectional Study. Lung 196:49-57
Rahimi, Rod A; Luster, Andrew D (2018) Chemokines: Critical Regulators of Memory T Cell Development, Maintenance, and Function. Adv Immunol 138:71-98
Muthalaly, Rahul G; Koplan, Bruce A; Albano, Alfred et al. (2018) Low population prevalence of atrial fibrillation in rural Uganda: A community-based cross-sectional study. Int J Cardiol 271:87-91
Xu, Shuying; Feliu, Marianela; Lord, Allison K et al. (2018) Biguanides enhance antifungal activity against Candida glabrata. Virulence 9:1150-1162
Arroyo, Anna J Chen; Robinson, Lacey B; Downing, N Lance et al. (2018) Occupational exposures and asthma prevalence among US farmworkers: National Agricultural Workers Survey, 2003-2014. J Allergy Clin Immunol Pract 6:2135-2138.e2
Dagher, Zeina; Xu, Shuying; Negoro, Paige E et al. (2018) Fluorescent Tracking of Yeast Division Clarifies the Essential Role of Spleen Tyrosine Kinase in the Intracellular Control of Candida glabrata in Macrophages. Front Immunol 9:1058
Sokol, Caroline L; Camire, Ryan B; Jones, Michael C et al. (2018) The Chemokine Receptor CCR8 Promotes the Migration of Dendritic Cells into the Lymph Node Parenchyma to Initiate the Allergic Immune Response. Immunity 49:449-463.e6
Robinson, Lacey B; Camargo Jr, Carlos A (2018) Acid suppressant medications and the risk of allergic diseases. Expert Rev Clin Immunol 14:771-780

Showing the most recent 10 out of 52 publications